CLRB

Cellectar Biosciences Inc

• NASDAQ·5d ago

  Cellectar Biosciences Eyes 2027 FDA Filing For Iopofosine In Waldenström Patients

• TipRanks·5d ago

  Cellectar Biosciences presents efficacy data from CLOVER WaM trial

• Benzinga·10/06 12:05

  12 Health Care Stocks Moving In Tuesday's Pre-Market Session

• NASDAQ·09/29 11:53

  Cellectar's Iopofosine I 131 Shows Positive Data In Waldenström Macroglobulinemia

• TipRanks·09/29 11:40

  Cellectar Biosciences to present data from Phase 2 CLOVER WaM trial

• TipRanks·08/22 00:24

  Cellectar Biosciences Earnings Call Highlights Clinical Momentum

• TipRanks·08/17 08:00

  Cellectar Biosciences reports Q2 EPS (57c), consensus (52c)

• TipRanks·08/14 16:55

  Cellectar: Solid Cash Runway and De-Risking Clinical Milestones Support Buy Rating; $10 Price Target Reiterated

• TipRanks·08/14 16:31

  Cellectar’s New Phase 3 WM Trial Puts Iopofosine I 131 on Investors’ Radar

• Benzinga·08/14 16:17

  Cellectar Biosciences 13G Filing Shows Balyasny Asset Management Reports 9.99% Stake In Co As Of June 30, 2026, Holding 798,382 Shares And Warrants

• Benzinga·08/14 16:17

  Cellectar Biosciences 13G Filing Shows StemPoint Capital Reports 9.99% Stake In Co As Of June 30, 2026, Holding 845,740 Shares Including Pre-Funded Warrants

• TipRanks·08/14 12:10

  Analysts Offer Insights on Healthcare Companies: Cellectar Biosciences (CLRB), NeuroOne Medical Technologies (NMTC) and Centene (CNC)

• Benzinga·08/13 13:19

  Cellectar Biosciences Q2 2026 Earnings Call Transcript

• NASDAQ·08/13 11:57

  Cellectar Reports Q2 2026 Results, Strengthened Cash Positions Supports Oncology Pipeline

• Seeking Alpha·08/13 11:19

  Cellectar Biosciences GAAP EPS of -$0.57 misses by $0.05